Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15287110 | 0.78 | KDM4E (0.36) | — | |
| SCHEMBL207358 | 0.77 | ALDH1A1 (0.30) | — | |
| SCHEMBL149760 | 0.74 | TSHR (0.37) | — | |
| SCHEMBL262756 | 0.74 | NT5E (0.30) | NT5E | |
| SCHEMBL21630340 | 0.74 | MAPT (0.40) | — | |
| SCHEMBL457652 | 0.73 | KIF11 (0.32) | — | |
| SCHEMBL101479 | 0.73 | PDK2 (0.31) | — | |
| SCHEMBL28250187 | 0.73 | TSHR (0.35) | — | |
| SCHEMBL5463356 | 0.73 | TSHR (0.40) | — | |
| SCHEMBL696976 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-01-05 | — | — | US | claimed |
| EP-3102034-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC Foundation For Research Development (US) | 2016-12-14 | — | — | EP | claimed |
| CN-103347865-B | Herbicidal compounds | SYNGENTA LTD. (GB) | 2016-02-03 | — | — | CN | claimed |
| EP-2220056-B1 | HERBICIDAL COMPOUNDS | SYNGENTA LTD (GB) | 2015-09-30 | — | — | EP | claimed |
| WO-2015120281-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-08-13 | — | — | WO | claimed |
| CN-101151244-B | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI | 2014-09-03 | — | — | CN | claimed |
| CN-102421783-B | Herbicidal compounds | SYNGENTA LTD | 2014-08-06 | — | — | CN | claimed |
| CN-101600700-B | Novel 2-amino oxazolines as TAAR1 ligands for CNS disorders | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | claimed |
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | claimed |
| CN-101910138-B | Herbicidal compounds | SYNGENTA LTD | 2013-06-26 | — | — | CN | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| CN-1668601-A | N-substituted tricyclic 3-aminopyrazoles as PDFG receptor inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-14 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| EP-0998451-B1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-04-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001968-A1 | AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS | KDM1A, KDM1B, KDM3A | NT5E 2882/4885KDM1A 1/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | NT5E 593/4885KDM1A 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.